Literature DB >> 24074567

Chemical cross-linking of HIV-1 Env for direct TLR7/8 ligand conjugation compromises recognition of conserved antigenic determinants.

Yu Feng1, Mattias N E Forsell, Barbara Flynn, William Adams, Karin Loré, Robert Seder, Richard T Wyatt, Gunilla B Karlsson Hedestam.   

Abstract

Covalent conjugation of immune-stimulatory compounds to protein antigens is a potential means to self-adjuvant non-replicating subunit vaccines. Previously, it was demonstrated that covalent coupling of a Toll-like receptor (TLR) ligand to the exterior HIV-1 envelope glycoprotein, gp120, enhanced its immunogenicity. However, the consequences of chemical conjugation to gp120 on broadly neutralizing antibody (bNAb) epitopes were so far not examined. Here, we conjugated a TLR7/8 ligand to lysine residues on gp120 using NHS-PEO8-maleimide linkers and investigated if this affected Ab recognition of the CD4 binding site (CD4bs), a highly conserved target for bNAbs. We demonstrate that the recognition of the CD4bs was reduced following coupling, especially at a higher coupling ratio. These results have implications for the coupling of ligands to vaccine antigens where elicitation of humoral immune responses to specific neutralizing determinants is desired.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cross-linker; HIV-1 envelope glycoprotein; Neutralizing antibody; Toll-like receptor ligand

Mesh:

Substances:

Year:  2013        PMID: 24074567      PMCID: PMC3800776          DOI: 10.1016/j.virol.2013.07.028

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  39 in total

Review 1.  Inflammasomes: far beyond inflammation.

Authors:  Jorge Henao-Mejia; Eran Elinav; Till Strowig; Richard A Flavell
Journal:  Nat Immunol       Date:  2012-03-19       Impact factor: 25.606

2.  Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major.

Authors:  Patricia A Darrah; Dipti T Patel; Paula M De Luca; Ross W B Lindsay; Dylan F Davey; Barbara J Flynn; Søren T Hoff; Peter Andersen; Steven G Reed; Sheldon L Morris; Mario Roederer; Robert A Seder
Journal:  Nat Med       Date:  2007-06-10       Impact factor: 53.440

Review 3.  Novel adjuvants for B cell immune responses.

Authors:  Karin Loré; Gunilla B Karlsson Hedestam
Journal:  Curr Opin HIV AIDS       Date:  2009-09       Impact factor: 4.283

Review 4.  The role of antibodies in HIV vaccines.

Authors:  John R Mascola; David C Montefiori
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

Review 5.  Regulation of inflammasome signaling.

Authors:  Vijay A K Rathinam; Sivapriya Kailasan Vanaja; Katherine A Fitzgerald
Journal:  Nat Immunol       Date:  2012-03-19       Impact factor: 25.606

6.  The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals.

Authors:  Peter D Crompton; Marko Mircetic; Greta Weiss; Amy Baughman; Chiung-Yu Huang; David J Topham; John J Treanor; Iñaki Sanz; F Eun-Hyung Lee; Anna P Durbin; Kazutoyo Miura; David L Narum; Ruth D Ellis; Elissa Malkin; Gregory E D Mullen; Louis H Miller; Laura B Martin; Susan K Pierce
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

7.  Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

Authors:  Andreas Wack; Barbara C Baudner; Anne K Hilbert; Ilaria Manini; Sandra Nuti; Simona Tavarini; Hanno Scheffczik; Mildred Ugozzoli; Manmohan Singh; Jina Kazzaz; Emanuele Montomoli; Giuseppe Del Giudice; Rino Rappuoli; Derek T O'Hagan
Journal:  Vaccine       Date:  2007-12-07       Impact factor: 3.641

8.  Human B cell responses to TLR ligands are differentially modulated by myeloid and plasmacytoid dendritic cells.

Authors:  Iyadh Douagi; Cornelia Gujer; Christopher Sundling; William C Adams; Anna Smed-Sörensen; Robert A Seder; Gunilla B Karlsson Hedestam; Karin Loré
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

Review 9.  The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.

Authors:  Gunilla B Karlsson Hedestam; Ron A M Fouchier; Sanjay Phogat; Dennis R Burton; Joseph Sodroski; Richard T Wyatt
Journal:  Nat Rev Microbiol       Date:  2008-02       Impact factor: 60.633

Review 10.  NLRs, inflammasomes, and viral infection.

Authors:  Sarah R Jacobs; Blossom Damania
Journal:  J Leukoc Biol       Date:  2012-05-10       Impact factor: 4.962

View more
  7 in total

Review 1.  Native-like Env trimers as a platform for HIV-1 vaccine design.

Authors:  Rogier W Sanders; John P Moore
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

2.  A tractable covalent linker strategy for the production of immunogenic antigen-TLR7/8L bioconjugates.

Authors:  C J Massena; S K Lathrop; C J Davison; R Schoener; H G Bazin; J T Evans; D J Burkhart
Journal:  Chem Commun (Camb)       Date:  2021-05-11       Impact factor: 6.065

3.  Conjugation of a Toll-Like Receptor Agonist to Glycans of an HIV Native-Like Envelope Trimer Preserves Neutralization Epitopes.

Authors:  Zeshi Li; Ronald Derking; Wen-Hsin Lee; Gerlof P Bosman; Andrew B Ward; Rogier W Sanders; Geert-Jan Boons
Journal:  Chembiochem       Date:  2022-06-20       Impact factor: 3.461

Review 4.  Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators.

Authors:  Elke S Bergmann-Leitner; Wolfgang W Leitner
Journal:  Vaccines (Basel)       Date:  2014-04-10

Review 5.  Designs of Antigen Structure and Composition for Improved Protein-Based Vaccine Efficacy.

Authors:  Kyle Saylor; Frank Gillam; Taylor Lohneis; Chenming Zhang
Journal:  Front Immunol       Date:  2020-02-24       Impact factor: 7.561

6.  Multifunctional Protein Conjugates with Built-in Adjuvant (Adjuvant-Protein-Antigen) as Cancer Vaccines Boost Potent Immune Responses.

Authors:  Jing-Jing Du; Chang-Wei Wang; Wen-Bo Xu; Lian Zhang; Yuan-Kai Tang; Shi-Hao Zhou; Xiao-Fei Gao; Guang-Fu Yang; Jun Guo
Journal:  iScience       Date:  2020-02-24

Review 7.  Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants.

Authors:  Sachin Bhagchandani; Jeremiah A Johnson; Darrell J Irvine
Journal:  Adv Drug Deliv Rev       Date:  2021-05-29       Impact factor: 15.470

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.